| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jude Canon, Rebecca Bryant, Martine Roudier, Tao Osgood, Jon Jones, Robert Miller, Angela Coxon, Robert Radinsky, William C Dougal. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone. vol 46. issue 6. 2010-08-25. PMID:20215062. |
the epidermal growth factor receptor (egfr) pathway regulates critical processes such as cell growth and survival, and anti-egfr therapies can cause tumor cell arrest and apoptosis. |
2010-08-25 |
2023-08-12 |
human |
| Bruno Vincenzi, Alice Zoccoli, Francesco Pantano, Olga Venditti, Sara Galluzz. Cetuximab: from bench to bedside. Current cancer drug targets. vol 10. issue 1. 2010-08-04. PMID:20088790. |
cetuximab binding to the egfr blocks phosphorylation and activation of receptor-associated kinases and their associated downstream signalling (mapk, pi3k/akt, jak/stat pathways) resulting in inhibition of many cellular processes such as induction of apoptosis, cell growth, decreased matrix metallo-proteinase (mmps) and vascular endothelial growth factor (vegf) production. |
2010-08-04 |
2023-08-12 |
mouse |
| Roberto E Favoni, Alessandra Pattarozzi, Michele Lo Casto, Federica Barbieri, Monica Gatti, Laura Paleari, Adriana Bajetto, Carola Porcile, Giovanni Gaudino, Luciano Mutti, Giorgio Corte, Tullio Flori. Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. Current cancer drug targets. vol 10. issue 2. 2010-07-22. PMID:20088784. |
cell proliferation, dna synthesis and apoptosis were measured by mtt, thymidine incorporation and facs analysis; egfr, erk1/2 and akt expression and phosphorylation by western blot, whereas receptor sites were analyzed by binding studies. |
2010-07-22 |
2023-08-12 |
human |
| Roberto E Favoni, Alessandra Pattarozzi, Michele Lo Casto, Federica Barbieri, Monica Gatti, Laura Paleari, Adriana Bajetto, Carola Porcile, Giovanni Gaudino, Luciano Mutti, Giorgio Corte, Tullio Flori. Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. Current cancer drug targets. vol 10. issue 2. 2010-07-22. PMID:20088784. |
low concentrations of gefitinib cause mesothelioma cell cycle arrest through the blockade of egfr activity while high concentrations induce apoptosis. |
2010-07-22 |
2023-08-12 |
human |
| Ranjita Banerjee, Ying Huang, James P McNamee, Margarita Todorova, Bertrand J Jean-Claud. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. The Journal of pharmacology and experimental therapeutics. vol 334. issue 1. 2010-07-13. PMID:20348204. |
cell response to this novel targeting mechanism was mediated by 1) activation of c-jun nh(2)-terminal kinase in response to dna damage and 2) down-regulation of bad through blockade of egfr tyrosine kinase activity: two events that cooperatively converged into enhancement of apoptosis in the oncogene-transfected cells. |
2010-07-13 |
2023-08-12 |
human |
| Hu Zhu, Xinyu Cao, Francis Ali-Osman, Stephen Keir, Hui-Wen L. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer letters. vol 294. issue 1. 2010-07-07. PMID:20153921. |
egfr and egfrviii interact with puma to inhibit mitochondrial translocalization of puma and puma-mediated apoptosis independent of egfr kinase activity. |
2010-07-07 |
2023-08-12 |
Not clear |
| Jing Li, Yang Meng, Yue Liu, Zhi-Qiang Feng, Xiao-Guang Che. F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies. Investigational new drugs. vol 28. issue 2. 2010-06-29. PMID:19214386. |
while the mechanism of action is still unclear, it might be related to inhibition of egfr signaling pathway, delay in cell cycle progression and a g1 arrest together with a partial g2/m block and induction of apoptosis. |
2010-06-29 |
2023-08-12 |
human |
| Z-B Liu, Y-F Hou, J Zhu, D-L Hu, W Jin, Z-L Ou, G-H Di, J Wu, Z-Z Shen, Z-M Sha. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene. vol 29. issue 20. 2010-06-16. PMID:20228837. |
the mannose cocultured test was used to detect the effect of mannose on pa-msha-induced cell proliferation, cell cycle arrest, apoptosis, and egfr pathway signaling. |
2010-06-16 |
2023-08-12 |
mouse |
| Z-B Liu, Y-F Hou, J Zhu, D-L Hu, W Jin, Z-L Ou, G-H Di, J Wu, Z-Z Shen, Z-M Sha. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene. vol 29. issue 20. 2010-06-16. PMID:20228837. |
the addition of mannose partially inhibited the pa-msha-stimulated cell anti-proliferative effect, cell apoptosis, cell cycle arrest, activation of apoptosis-associated caspases, and even downregulation of the egfr signaling pathway. |
2010-06-16 |
2023-08-12 |
mouse |
| M K Addepalli, K B Ray, B Kumar, R L Ramnath, S Chile, H Ra. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene therapy. vol 17. issue 3. 2010-06-14. PMID:19956271. |
aurkb and egfr sirna in combination have shown enhanced therapeutic effect by inhibiting pc3 cell proliferation and inducing apoptosis in vitro, whereas androgen-dependent cancer cells lncap remain unaffected correlating the endogenous expression levels. |
2010-06-14 |
2023-08-12 |
mouse |
| Taghrid B El-Abaseri, Laura A Hanse. EGFR activation and ultraviolet light-induced skin carcinogenesis. Journal of biomedicine & biotechnology. vol 2007. issue 3. 2010-06-10. PMID:17541473. |
uv-induced egfr activation increases keratinocyte proliferation, suppresses apoptosis, and augments and accelerates epidermal hyperplasia in response to uv. |
2010-06-10 |
2023-08-12 |
mouse |
| Hideki Shimodaira, Keigo Komine, Hiroshi Soeda, Chikashi Ishiok. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody]. Gan to kagaku ryoho. Cancer & chemotherapy. vol 37. issue 5. 2010-06-10. PMID:20495309. |
egfr constitute an attractive target for tumor therapy, because it is a transmembrane receptor tyrosine kinase which is critically involved in tumorigenesis by stimulating cell proliferation and inhibiting apoptosis or other biological functions. |
2010-06-10 |
2023-08-12 |
Not clear |
| Takashi Nakano, Tatsuya Ohno, Hitoshi Ishikawa, Yoshiyuki Suzuki, Takeo Takahash. Current advancement in radiation therapy for uterine cervical cancer. Journal of radiation research. vol 51. issue 1. 2010-05-25. PMID:20173313. |
the biological factors overviewed in this article include hypoxia relating factors of hif-1alpha, sod, cell cycle parameters of pmi, proliferation factors of ki67, egfr, cerbb2, cox-2, cycle regulation proteins p53, p21, apoptosis regulation proteins bcl2 and bax and so on. |
2010-05-25 |
2023-08-12 |
human |
| Carter Van Waes, Clint T Allen, Deborah Citrin, David Gius, A Dimetrios Colevas, Nancy A Harold, Susan Rudy, Liesl Nottingham, Christine Muir, Zhong Chen, Anurag K Singh, Janet Dancey, John C Morri. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics. vol 77. issue 2. 2010-05-24. PMID:19879702. |
epidermal growth factor receptor (egfr) overexpression in head-and-neck squamous cell carcinoma (hnscc) stimulates tumor cell proliferation, inhibits apoptosis, and increases chemotherapy and radiation resistance. |
2010-05-24 |
2023-08-12 |
Not clear |
| L C Heukamp, R Büttne. [Molecular diagnostics in lung carcinoma for therapy stratification]. Der Pathologe. vol 31. issue 1. 2010-05-24. PMID:19997736. |
since epidermal growth factor receptor (egfr) is overexpressed in 80% of cases of non-small cell lung carcinoma, mediating important carcinogenic properties such as cell-cycle progression, apoptosis, angiogenesis and metastasis, it is considered a relevant target in novel specific therapies. |
2010-05-24 |
2023-08-12 |
Not clear |
| Hiroyuki Michiue, Akiko Eguchi, Miriam Scadeng, Steven F Dowd. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer biology & therapy. vol 8. issue 23. 2010-05-20. PMID:19901546. |
combinatorial targeting of egf-receptor (egfr) and akt2, but not ak1 or akt3, by ptd-drbd delivered sirnas synergized to induce tumor cell specific apoptosis. |
2010-05-20 |
2023-08-12 |
mouse |
| Hiroyuki Michiue, Akiko Eguchi, Miriam Scadeng, Steven F Dowd. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer biology & therapy. vol 8. issue 23. 2010-05-20. PMID:19901546. |
in vivo ptd-drbd delivery of egfr and akt2 sirnas induced tumor specific apoptosis and significantly increased survival in intracerebral glioblastoma mouse models (p < 0.0005), whereas delivery of irrelevant control sirnas did not alter longevity. |
2010-05-20 |
2023-08-12 |
mouse |
| Apar Kishor Gant. Epidermal growth factor receptor signaling in nonsmall cell lung cancer. Cancer investigation. vol 28. issue 5. 2010-05-14. PMID:20073576. |
egfr function is dysregulated in various malignancies including nonsmall cell lung cancer (nsclc) leading to activation of several signal transduction pathways including k-ras, pik3, and stat3 and stat5, that promote cell cycle progression, proliferation, invasion, angiogenesis, and inhibit apoptosis. |
2010-05-14 |
2023-08-12 |
Not clear |
| Soumya Jaganathan, Peibin Yue, James Turkso. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. The Journal of pharmacology and experimental therapeutics. vol 333. issue 2. 2010-05-10. PMID:20100905. |
by contrast, the concurrent inhibition of stat3 and egfr or src induced greater viability loss and apoptosis and decreased the migration/invasion of pancreatic cancer cells in vitro. |
2010-05-10 |
2023-08-12 |
human |
| Hyun Seung Ban, Yuko Tanaka, Wataru Nabeyama, Masako Hatori, Hiroyuki Nakamur. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines. Bioorganic & medicinal chemistry. vol 18. issue 2. 2010-04-27. PMID:19969465. |
these compounds inhibited egf-mediated phosphorylation of egfr in a431 cells, resulting in cell-cycle arrest and apoptosis induction. |
2010-04-27 |
2023-08-12 |
Not clear |